From Nobel to Nasdaq: Turning Breakthrough Science Into Impact
From Nobel to Nasdaq: Turning Breakthrough Into Biotech Impact
What happens after a Nobel Prize is awarded? How do fundamental scientific discoveries translate into companies, therapies, and real-world impact?
Following the 2025 Nobel Prize in Physiology or Medicine for discoveries in peripheral immune tolerance and regulatory T cells (Tregs), this event explores how foundational immunology can evolve into biotech innovation and global clinical progress.
From Nobel to Nasdaq brings together leaders from academia, biotech, innovation, and investment to discuss the full translational pathway — from discovery to company formation, venture funding, and public markets.
On the panel:
Daniel Sheward, PhD, Assistant Professor at Karolinska Institutet, will outline the scientific significance of Treg biology and its implications for emerging therapies.
Anton Lindqvist, Chief Scientific Officer at Diamyd Medical, will share insights into how academic research is developed into clinical-stage therapeutics.
Johan Weigelt, PhD, CEO at KI Innovations, will discuss commercialization strategies and the role of innovation ecosystems in company creation.
Magnus Klaesson, Co-founder of Life Science Invest AB, will provide the investor perspective on building and scaling biotech ventures.
The discussion will be moderated by Armando Cázares-Körner.
Hosted at The Park Forskaren in Hagastaden and organized by Nucleate, the event is supported by partners including Vectura and Chiesi.
The 60-minute panel will be followed by networking and refreshments, offering an opportunity to connect with researchers, founders, biotech executives, investors, and policy leaders across the Stockholm life sciences community.